OBIO — Orchestra Biomed Holdings Income Statement
0.000.00%
Last trade - 00:00
- $174.95m
- $87.36m
- $2.76m
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 8-K | 8-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 5.7 | -0.782 | 3.53 | 2.76 |
Cost of Revenue | ||||
Gross Profit | 5.56 | -0.981 | 3.32 | 2.57 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Unusual Expense / Income | ||||
Total Operating Expenses | 24.5 | 21 | 36.9 | 55.4 |
Operating Profit | -18.8 | -21.8 | -33.3 | -52.7 |
Total Net Non Operating Interest Income / Expense | ||||
Total Net Non Operating Interest Income / Expense | ||||
Net Income Before Taxes | -21.4 | -23 | -33.6 | -49.1 |
Net Income After Taxes | -21.4 | -23 | -33.6 | -49.1 |
Net Income Before Extraordinary Items | ||||
Net Income | -21.4 | -23 | -33.6 | -49.1 |
Adjustments to Net Income | ||||
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -21.4 | -23 | -35.6 | -49.1 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.675 | -0.728 | -1.1 | -1.44 |
Dividends per Share |